HYBRID EVENT: You can participate in person at Rome, Itlay or Virtually from your home or work.

11th Edition of International Conference on

Neurology and Neurological Disorders

June 05-07, 2025 | Rome, Italy

Tauopathies

Tauopathies

Tauopathies are a group of neurological disorders characterized by the accumulation of abnormal aggregates of the microtubule associated protein Tau in neurons in the brain. Tau accumulation contributes to the injury and death of neurons, resulting in a range of manifestations from mild cognitive impairment to coma and death. Tauopathies are autosomal dominant neurological disorders. Early signs of tauopathy include subtle changes in behavior, language, and vision, as well as memory deficits and struggles with executive functioning. As the disease progresses into more advanced stages, difficulties walking, balance, and other motor functions can become more prominent. Tau accumulates in neurons as clusters of filamentous aggregates or neurofibrillary tangles. In normal neurons, tau binds to and stabilizes the microtubules. In tauopathies, the levels of tau in the brain are increased, resulting in impaired function of the microtubules and subsequent cell death. Various genetic mutations of tau (targeting the amino acid sequence of tau protein) have been associated with tauopathies, such as frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration. The exact causes of tauopathy are disputed. A variety of environmental, genetic, and physiological factors may all contribute to Tau accumulation. Oxidative stress, infection, age-related inflammation, and reduced activity of degradative pathways (such as autophagy) have all been proposed as potential sources of tauopathy. In addition, genetic sequencing of the Tau gene (MAPT) in individuals with tauopathies has identified a number of mutations that may contribute to tau accumulation. The diagnosis of tauopathies is primarily through clinical evaluation of symptoms and imaging. Biomarkers of tauopathy (e.g. CSF tau) may be used to aid in the diagnosis. Current treatments for tauopathies focus on symptomatic relief, mainly through medications that improve cognitive functions.  

Committee Members
Speaker at Neurology and Neurological Disorders 2025 - Ken Ware

Ken Ware

NeuroPhysics Therapy Institute, Australia
Speaker at Neurology and Neurological Disorders 2025 - Robert B Slocum

Robert B Slocum

University of Kentucky HealthCare, United States
Speaker at Neurology and Neurological Disorders 2025 - Luiz Moutinho

Luiz Moutinho

University of Suffolk, United Kingdom
Neurology 2025 Speakers
Speaker at Neurology and Neurological Disorders 2025 - David Lominadze

David Lominadze

University of South Florida, United States
Speaker at Neurology and Neurological Disorders 2025 - Milton C R Medeiros

Milton C R Medeiros

Irmandade Santa Casa de Arapongas PR, Brazil
Speaker at Neurology and Neurological Disorders 2025 - Sang Hie Lee

Sang Hie Lee

University of South Florida, United States
Speaker at Neurology and Neurological Disorders 2025 - Sergei M Danilov

Sergei M Danilov

University of Illinois, United States

Submit your abstract Today

Watsapp